GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Price-to-Tangible-Book

Tempest Therapeutics (Tempest Therapeutics) Price-to-Tangible-Book : 3.49 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Price-to-Tangible-Book?

As of today (2024-05-27), Tempest Therapeutics's share price is $3.245. Tempest Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.93. Hence, Tempest Therapeutics's Price to Tangible Book Ratio of today is 3.49.

The historical rank and industry rank for Tempest Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

TPST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.64   Med: 1.54   Max: 4.21
Current: 3.49

During the past 4 years, Tempest Therapeutics's highest Price to Tangible Book Ratio was 4.21. The lowest was 0.64. And the median was 1.54.

TPST's Price-to-Tangible-Book is ranked worse than
59.05% of 1221 companies
in the Biotechnology industry
Industry Median: 2.8 vs TPST: 3.49

A closely related ratio is called PB Ratio. As of today, Tempest Therapeutics's share price is $3.245. Tempest Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.93. Hence, Tempest Therapeutics's P/B Ratio of today is 3.49.


Tempest Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Tempest Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Price-to-Tangible-Book Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- 1.01 0.67 3.62

Tempest Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 3.19 - 3.62 4.21

Competitive Comparison of Tempest Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Tempest Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tempest Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Price-to-Tangible-Book falls into.



Tempest Therapeutics Price-to-Tangible-Book Calculation

Tempest Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=3.245/0.929
=3.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Tempest Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Tempest Therapeutics (Tempest Therapeutics) Business Description

Traded in Other Exchanges
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Executives
Justin Trojanowski officer: Corporate Controller C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas officer: VP of Strategy and Finance 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky director, officer: President C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting officer: Chief Medical Officer C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202

Tempest Therapeutics (Tempest Therapeutics) Headlines